The Horse:Your Guide To Equine Health Care provides monthly equine health care information to horse owners, breeders, veterinarians, barn/farm managers, trainer/riding instructors, and others involved in the hands-on care of the horse.
Issue link: https://thehorse.epubxp.com/i/570682
When it's EPM, treat with confidence. Ask your veterinarian for MARQUIS, the first FDA-approved treatment for EPM. The FirsT Approved T reATmenT For epm Equine protozoal myeloencephalitis (EPM) can cause permanent damage – even death. MARQUIS is the frst FDA-approved treatment for EPM. And with an easy-to-give paste, you'll know your horse is getting every important dose. MARQUIS ® (15% w/w ponazuril) Antiprotozoal Oral Paste Now a Merial® Equine brand. marquis.merial.com IMPORTANT SAFETY INFORMATION: The safe use of MARQUIS in horses used for breeding purposes, during pregnancy, or in lactating mares, has not been evaluated. In animal safety studies, loose feces, sporadic inappetence, lost weight, and moderate edema in the uterine epithelium were observed. Marquis® (15% w/w ponazuril) Antiprotozoal Oral Paste, BRIEF SUMMARY: Before using Marquis, please consult the product insert, a summary of which follows: CAUTION: Federal (U.S.A.) Law restricts this drug to use by or on the order of a licensed veterinarian. INDICATIONS: Marquis (ponazuril) is indicated for the treatment of equine protozoal myeloencephalitis (EPM) caused by Sarcocystis neurona. WARNINGS: For use in animals only. Not for use in horses intended for food. Not for human use. Keep out of reach of children. PRECAUTIONS: Prior to treatment, a complete neurologic exam should be completed by a veterinarian. In most instances, ataxia due to EPM is asymmetrical and afects the hind limbs. Clinicians should recognize that clearance of the parasite by ponazuril may not completely resolve the clinical signs attributed to the natural progression of the disease. The prognosis for animals treated for EPM may be dependent upon the severity of disease and the duration of the infection prior to treatment. The safe use of Marquis (ponazuril) in horses used for breeding purposes, during pregnancy, or in lactating mares, has not been evaluated. The safety of Marquis (ponazuril) with concomitant therapies in horses has not been evaluated. ADVERSE REACTIONS: In the feld study, eight animals were noted to have unusual daily observations. Two horses exhibited blisters on the nose and mouth, three animals showed skin reactions for up to 18 days, one animal had loose stools, one had a mild colic on one day and one animal had a seizure while on medication. The association of these reactions to treatment was not established. ANIMAL SAFETY SUMMARY: Marquis (ponazuril) was administered to 24 adult horses (12 males and 12 females) in a target animal safety study. Three groups of 8 horses each received 0, 10 or 30 mg/kg (water as control, 2X and 6X for a 5 mg/kg [2.27 mg/lb] dose). Horses were dosed after feeding. One half of each group was treated for 28 days and the other half for 56 days followed by necropsy upon termination of treatment. There were several instances of loose feces in all animals in the study irrespective of treatment, sporadic inappetence and one horse at 10 mg/kg (2X) lost weight while on test. Loose feces were treatment related. Histopathological fndings included moderate edema in the uterine epithelium of three of the four females in the 6X group (two treated for 28 days and one for 56 days). For customer care or to obtain product information, including a Material Safety Data Sheet, call 1-888-637-4251 Option 2, then press 1. ®MERIAL and MARQUIS are registered trademarks of Merial. ©2015 Merial, Inc., Duluth, GA. All rights reserved. EQUIOMQ1506 (03/15)